Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders, NORSE THREE

NCT04516278 is registered in ClinicalTrials.gov with Outlook Therapeutics, Inc. as lead sponsor.

NCT NCT04516278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04516278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders, NORSE THREE
Lead sponsor
Outlook Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 1, 2020
Completion date
February 10, 2021
Enrollment
197 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, brvo - branch retinal vein occlusion, diabetic macular edema, neovascular age-related macular degeneration, wet macular degeneration